Edwards Lifesciences (EW) Reports In-Line Q3 EPS
Tweet
Share
E-mail
Get Alerts EW Hot Sheet
Price: $92.21 +0.96%
Revenue Growth %: +11.1%
Financial Fact:
Research and development expenses: 113.1M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +11.1%
Financial Fact:
Research and development expenses: 113.1M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.54, in-line with the analyst estimate of $0.54. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.33 billion.
GUIDANCE:
Edwards Lifesciences sees Q4 2021 EPS of $0.53-$0.59, versus the consensus of $0.56. Edwards Lifesciences sees Q4 2021 revenue of $1.3-1.38 billion, versus the consensus of $1.41 billion.
For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- What Delta’s report tells investors in American and United
- Delta Air Lines stock climbs on earnings beat and strong guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
